Anavex Life Sciences Corp. develops investigational oral therapies aimed at improving brain health, focusing on neurodegenerative and neurodevelopmental diseases. Its lead candidate, ANAVEX®2-73 (blarcamesine), is being studied for its potential to support cellular health and slow neurodegeneration in conditions such as Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company conducts clinical trials to evaluate the efficacy of its therapies, targeting mechanisms like autophagy to address the underlying challenges of these disorders.
